Immunotherapy

 

The immune system is a system of cells and organs whose function is to defend an organism from foreign pathogens. With the ability to mount a response against virtually any foreign material and return to a quiescent state following neutralization of the threat, this fascinating organ system displays remarkable specificity and plasticity. To achieve this, there is a multifaceted balancing act between the many activators and suppressors that maintains homeostasis of perhaps the body’s most complex organ system.

Activation of the immune system involves a number of checkpoints in order to ensure proper activation. For instance, T cell activation requires binding of the T cell receptor to the MHC antigen, yet this interaction alone is not sufficient for producing a T cell response. Full T cell activation and inactivation requires the coordination of a multitude of co-stimulatory and inhibitory signals. For example, T cell activation can result from the combination of MHC:TCR and B7-1:CD28 interaction. In contrast, B7-1 binding to CTLA4 results in an inhibitory signal that prevents activation.

Given its diverse function and the fact that the immune system plays a role in virtually all human diseases, immunotherapy has become an important approach for the treatment of numerous diseases. Immunotherapy is defined as the treatment of disease by inducing, enhancing, or suppressing an immune response. This often involves targeting immunoreceptors, such as those discussed above, with small molecule inhibitors/activators or immune system components, including antibodies or antibody fragments (Fab). Immunotherapies have shown efficacy in the treatment of cancer, autoimmune diseases, inflammatory diseases, and more.

BPS Bioscience offers many purified, soluble immunoreceptors involved in key immunosignaling pathways. Additionally, we offer a number of assay kits that can be used to screen for inhibitors of protein-protein interaction, as well as neutralizing antibodies to serve as positive controls for inhibition.

References:

1.  Pardoll, D.M., Nat. Rev. Cancer. 2012; 12: 252-264.
2.  Lesterhuis, W.J., et al., Nat. Rev. Drug. Disc. 2011; 10: 591-600.

Immunotherapy Subcategories

Items 76 to 100 of 401 total

per page
Page:
  1. 2
  2. 3
  3. 4
  4. 5
  5. 6

Catalog#SizeProduct NamePrice
71250 100 μg CD137, Fc fusion (hIgG1) (Mouse)
$300
71254 100 µg CD137, Fc fusion (mIgG2a), Avi-tag (Mouse) HiP™
$300
71255 50 µg CD137, Fc fusion (mIgG2a), Biotin-labeled (Mouse) HiP™
$405
79289 2 vials CD137/NF-κB Reporter - HEK293 Recombinant Cell Line Contact us for pricing
71189 100 µg CD137L (4-1BB ligand), His-tag
$300
60523 2 vials CD137L (4-1BBL) CHO-K1 Recombinant Cell Line Contact us for pricing
72517 100 µg CD137L, His-Tag (Mouse)
$300
72025 96 reactions CD137[Biotinylated]:CD137L Inhibitor Screening Assay Kit
$995
72307 50 μg CD150, Fc Fusion (IgG1), Biotin Labeled (Human)
$405
72304 100 μg CD150, Fc Fusion, Avi-Tag (Human)
$310
60537 2 vials CD155 (PVR) - HEK293 Recombinant Cell Line Contact us for pricing
71181 100 µg CD155 (PVR), His-tag (Human)
$300
71167 100 µg CD155 (PVR), His-tag (Mouse) HiP™
$300
60548 2 vials CD155 / TCR Activator - CHO Recombinant Cell line Contact us for pricing
71168 50 µg CD155, His-tag, Biotin-labeled (Mouse) HiP™
$405
71173 100 µg CD160, His-tag (Human) HiP™
$300
71135 50 µg CD160, His-tag, Biotin-labeled (Human) HiP™
$405
71264 100 μg CD2, Fc fusion, Avi-Tag, (Human) HiP™
$310
71270 50 µg CD2, Fc fusion, Biotin-labeled (Human) HiP™
$405
71252 100 µg CD226, Fc fusion (Human) HiP™
$300
71253 50 µg CD226, Fc fusion, Biotin-labeled (Human) HiP™
$405
72051 384 reactions CD226:CD112 Homogeneous Assay Kit
$295
72052 384 reactions CD226:CD155 Homogeneous Assay Kit
$295
72305 100 μg CD244, Fc Fusion (IgG1), Avi-Tag (Human)
$310
72306 50 μg CD244, Fc Fusion (IgG1), Biotin-Labeled (Human)
$405

Items 76 to 100 of 401 total

per page
Page:
  1. 2
  2. 3
  3. 4
  4. 5
  5. 6